COVID-19 roundup: BioNTech, Pfizer co-developing vaccine, plus updates from Regeneron, Novartis, CureVac, Fujifilm and CanSino
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Biopharma companies stretching from Asia to the U.S. and Europe Tuesday announced a flurry of deals, new initiatives and clinical updates for therapeutic and vaccine approaches to address the COVID-19 pandemic, including a partnership between BioNTech and Pfizer that sent the German mRNA player’s value up nearly $7 billion.
BioNTech SE (NASDAQ:BNTX) climbed $26.60 (67%) to $66.60 on Tuesday, giving it a market cap of nearly $17 billion, after announcing a co-development agreement with Pfizer Inc. (NYSE:PFE) for BNT162, the biotech’s mRNA-based COVID-19 vaccine candidate. The urgency to develop the program is marked by the fact the partners expect to start the collaboration immediately while financial terms of the deal are finalized over the coming weeks. The companies partnered in 2018 to develop an influenza vaccine...